



ISPOR Serbia Chapter Annual Report 2014

TO:

Board of Directors

International Society for Pharmacoeconomics and Outcomes Research
505 Lawrence Square Blvd South
Lawrenceville, NJ 08648 USA

PREPARED BY:

Dragana Atanasijevic, MSc

HTA Consultant, ISPOR Serbia chapter President elect

Tel: +381 (060) 0100-832

Email: dratanas@yahoo.com

Background:

The ISPOR Serbia Chapter was approved in May 2007. The chapter has 70 members.

The current leadership of the ISPOR Serbia Chapter is comprised of the following:

President	Prof. Dragomir Marisavljevic, PhD Professor, Institute for Hematology, Beograd, Serbia
President-Elect	Dragana Atanasijevic, MSc HTA Consultant, Ministry of Health Serbia, Belgrade, Serbia
Past-President	Vladimir Zah, PhD(c) Health Economics Consultant Belgrade, Serbia
Secretary/Treasurer	Prof. Nataša Bogavac-Stanojevic, PhD Assistant Professor, Faculty of Pharmacy, University of Belgrade, Serbia

For more information on the ISPOR Serbia Chapter, please visit the ISPOR Regional Chapter website at <http://www.ispor.org/RegionalChapters/Chapter/Serbia>.

Enclosure: ISPOR Serbia Chapter Annual Report 2014.

ISPOR Serbia Chapter Annual Report 2014

Activities / Accomplishments	Summary
Scientific / Educational Activities	<ol style="list-style-type: none"> 1. Module 1 Course: Introduction to Health Economics; Location: Belgrade 2. IDLP Module Translation to Serbian: Introduction to PE 3. Therapeutic and Diagnostic Devices Outcomes Research (TDDOR) Book translation, prepress
Policy-Related Activities	<ol style="list-style-type: none"> 1. Participation at ISPOR 23rd HTA Roundtable, during the <i>ISPOR 17th Annual European Congress</i> in Amsterdam, The Netherlands. 2. Chapter elections
Conferences and/or Chapter Meetings	<ol style="list-style-type: none"> 1. 1st Macedonian and 4th Adriatic Congress on Pharmacoeconomics and Outcomes, April 24-27, 2014, Ohrid, Republic of Macedonia. 2. 19th Annual International Meeting, May 31- June 4, 2014, Montreal, Canada 3. ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands
Membership Development	<ol style="list-style-type: none"> 1. Website, Fb and LinkedIn presentation of the Chapter activities running to keep our members and prospective members informed about our activities and activities in the region.

Upcoming Activities for ISPOR Serbia Chapter in 2015

Date	Activities
January	<ol style="list-style-type: none"> 1. Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report-translation 2. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis-translation 3. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies-translation 4. Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1-translation 5. The annual plan of courses
February	<ol style="list-style-type: none"> 1. TDDOR Serbian edition book launch meeting & promotion 2. Updating of the website, Contacts with members , raising the blog
March	<ol style="list-style-type: none"> 1. Amendment of the Statute and adjustment of all documents to the new conditions
May	Module 2 Course - Intro to Health Economics– BIM model workshop, Belgrade
Sept	Module 3 Course – Intro to Health Economics – Markov model workshop, Belgrade
Oct	Module 4 Course – Intro to Health Economics – CEA model workshop, Belgrade
Permanent	<ol style="list-style-type: none"> 1. Education - (preparation courses for accreditation, course and online course promotion and realization) 2. ISPOR Chapter Serbia newsletter running on a monthly basis to keep our members and prospective members informed about our activities and activities in the region

Permanent	Research - management and monitoring-joint action with ISPOR international 1. Application of MCDM analysis 2. The benefit of innovative medicines 3. Evaluation of policies and generic drugs and biosimilars 4. Adherence to therapy / RW outcomes (patient adherence/real world outcomes) 5. The importance of parallel imports 6. Policy access technologies with rare diseases in CEE region 7. Epidemiology and economics of the management of COPD
-----------	---